Abbott Laboratories
Abbott Laboratories Announces First-Quarter 2026 Results and Acquisition of Exact Sciences
Summary
Abbott Laboratories reported its first-quarter 2026 financial results, showing a 7.8% increase in total sales to $11.164 billion. The company also announced the completion of its acquisition of Exact Sciences, a leader in oncology diagnostics, which is expected to add a new high-growth vertical to Abbott's portfolio. Abbott projected full-year 2026 comparable sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.38 to $5.58, including $0.20 of dilution related to the acquisition. Additionally, Abbott declared a quarterly dividend of $0.63 per share, payable on May 15, 2026.
Get alerts for ABT
Be first to know when Abbott Laboratories files with the SEC.
Filing Categories
Advertisement
About Abbott Laboratories
Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.
Official SEC Documents
Advertisement